|Findings from the University of Colorado Boulder Nicotinamide Riboside Human Clinical Trial, to be Presented to the Scientific Community
IRVINE, Calif., July 10, 2017 (GLOBE NEWSWIRE) -- ChromaDex Corp. (NASDAQ:CDXC), an innovator of proprietary health, wellness, and nutritional ingredients that creates science-based solutions for dietary supplement, food and beverage, skin care, sports nutrition, and pharmaceutical products announced today it is a proud sponsor of the Federation of American Societies for Experimental Biology (FASEB) 2017 conference for NAD+ Metabolism and Signaling. The conference will bring together leading global experts in NAD+ biology with the objective of advancing the understanding of the molecule. This morning’s session will include a talk by Dr. Christopher Martens of the Integrative Physiology of Aging Laboratory at the University of Colorado Boulder (CU Boulder), who will present findings from his recently completed clinical trial of chronic nicotinamide riboside supplementation in middle-aged and older adults.
ChromaDex’s Founder and CEO, Frank Jaksch, stated, “As a company at the forefront of NR and NAD+ research, we continue to sponsor this meeting because we see collaboration as a catalyst of greater opportunity. We are thrilled that the results of the first chronic dose clinical trial of NIAGEN® will be shared amongst this elite community. This is an exciting step forward in advancing the science supporting nicotinamide riboside and its role in human health.”
Nicotinamide adenine dinucleotide (NAD+)– first called co-zymase more than 110 years ago for its essential role in the metabolism of glucose—is the central mediator of all metabolism. In recent years, regulatory roles of NAD+ have been discovered in DNA repair, gene expression and the maintenance of youthful resiliency. Recently, significant progress has been made in the understanding of NAD+, highlighting its broad relevance to human health and disease.
Dr. Charles Brenner, conference co-chair and Chief Scientific Advisor to ChromaDex, commented, “Eight years ago, John Denu and I organized the first FASEB Conference on NAD+ Metabolism and Signaling. Co-chairs Paul Chang, Anne-laure Perraud, Lenny Guarente, Mathias Ziegler and I have put together a who’s who of established and rising stars in all areas of NAD+ function. NAD+-boosting technologies are already making important contributions to human wellness and nutrition and meetings such as this are important for catalyzing research into the many vital systems to which NAD+ metabolism contributes.”
NAD+ is an essential coenzyme in cellular metabolism. Published research suggests that many aging-related health challenges are linked to NAD+ deficiency. NAD+ and its metabolites such as Nicotinamide Riboside (NR) have been the focus of intense scientific research and popular news media coverage due to their believed roles in healthy aging and extension of healthspan.
To date, ChromaDex has invested millions in safety, toxicology and human clinical trials on their ingredient, nicotinamide riboside (NR), which has been clinically demonstrated to safely and effectively increase NAD+ in human subjects. It has also initiated over 120 collaborative studies with leading universities and research institutions such as CU Boulder, the National Institute on Aging, MIT and the Scripps Research Institute representing an estimated $50 million in NR research.
For more information about ChromaDex, visit www.chromadex.com.
ChromaDex leverages its complementary business units to discover, acquire, develop and commercialize patented and proprietary ingredient technologies that address the dietary supplement, food, beverage, skin care and pharmaceutical markets. In addition to our ingredient technologies unit, we also have business units focused on natural product fine chemicals (known as "phytochemicals"), chemistry and analytical testing services, and product regulatory and safety consulting. As a result of our relationships with leading universities and research institutions, we are able to discover and license early stage, IP-backed ingredient technologies. We then utilize our in-house chemistry, regulatory and safety consulting business units to develop commercially viable ingredients. Our ingredient portfolio is backed with clinical and scientific research, as well as extensive IP protection. Our portfolio of patented ingredient technologies includes NIAGEN® nicotinamide riboside; pTeroPure® pterostilbene; PURENERGY®, a caffeine-pTeroPure® co-crystal; IMMULINA™, a spirulina extract; and AnthOrigin™, anthocyanins derived from a domestically-produced, water-extracted purple corn husk. To learn more about ChromaDex, please visit www.ChromaDex.com.
This release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities and Exchange Act of 1934, as amended, including statements related to the research behind NR, the results of NR studies, their significance and the opportunities related thereto. Statements that are not a description of historical facts constitute forward-looking statements and may often, but not always, be identified by the use of such words as "expects", "anticipates", "intends", "estimates", "plans", "potential", "possible", "probable", "believes", "seeks", "may", "will", "should", "could" or the negative of such terms or other similar expressions. More detailed information about ChromaDex and the risk factors that may affect the realization of forward-looking statements is set forth in ChromaDex's Annual Report on Form 10-K for the fiscal year ended December 31, 2016, ChromaDex's Quarterly Reports on Form 10-Q and other filings submitted by ChromaDex to the SEC, copies of which may be obtained from the SEC's website at www.sec.gov. Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof, and actual results may differ materially from those suggested by these forward-looking statements. All forward-looking statements are qualified in their entirety by this cautionary statement and ChromaDex undertakes no obligation to revise or update this release to reflect events or circumstances after the date hereof.
ChromaDex Public Relations Contact:
Breah Ostendorf, Director of Marketing
ChromaDex Investor Relations Contact:
Andrew Johnson, Director of Investor Relations